Jia JD - Search Results

1

Current challenges and the management of chronic hepatitis C in mainland China.

Duan Z, Jia JD, Hou J, Lou L, Tobias H, Xu XY, Wei L, Zhuang H, Pan CQ. Duan Z, et al. Among authors: jia jd. J Clin Gastroenterol. 2014 Sep;48(8):679-86. doi: 10.1097/MCG.0000000000000109. J Clin Gastroenterol. 2014. PMID: 24921215 Free PMC article. Review.

2

[Transitional CK19 positive cells-a new possible marker of hepatic precancerous lesion].

Chen Y, Duan ZP, Wang BE, Jia JD, Chen GY, Li YM. Chen Y, et al. Among authors: jia jd. Zhonghua Gan Zang Bing Za Zhi. 2004 Jan;12(1):38-9. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 14761282 Chinese.

3

[A clinical study of the efficacy and safety of secretory human interferon alpha-2a treatment for chronic hepatitis B].

Wang H, Wang QH, Wang HF, Jia JD, Xie W, Qin XQ. Wang H, et al. Among authors: jia jd. Zhonghua Gan Zang Bing Za Zhi. 2004 Oct;12(10):589-92. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15504287 Clinical Trial. Chinese.

4

[Therapeutic strategies for chronic hepatitis B recommended by the American Association for the Study of Liver Diseases].

Wang YC, Jia JD. Wang YC, et al. Among authors: jia jd. Zhonghua Gan Zang Bing Za Zhi. 2004 Oct;12(10):623-4. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15504297 Chinese. No abstract available.

5

[The overview of the seminar on chronic hepatitis B].

Jia JD, Zhuang H. Jia JD, et al. Zhonghua Gan Zang Bing Za Zhi. 2004 Nov;12(11):698-9. Zhonghua Gan Zang Bing Za Zhi. 2004. PMID: 15623388 Chinese. No abstract available.

6

[Management of HBeAg negative chronic hepatitis B].

Jia JD. Jia JD. Zhonghua Gan Zang Bing Za Zhi. 2005 Jul;13(7):539. Zhonghua Gan Zang Bing Za Zhi. 2005. PMID: 16042896 Chinese. No abstract available.

7

[How long should patients with chronic hepatitis B virus infection be treated].

Jia JD. Jia JD. Zhonghua Gan Zang Bing Za Zhi. 2006 Nov;14(11):835. Zhonghua Gan Zang Bing Za Zhi. 2006. PMID: 17125612 Chinese. No abstract available.

8

[The degree of HBV suppression with 24 week telbivudine- or lamivudine-treatment in hepatitis B patients predicts the efficacy of the treatment at week 52].

Jia JD, Hou JL, Yin YK, Xu DZ, Tan DM, Niu JQ, Zhou XQ, Wang YM, Zhu LM, He YW, Ren H, Wan MB, Chen CW, Wu SM, Chen YG, Xu JZ, Wang QH, Wei L, Ma H. Jia JD, et al. Zhonghua Gan Zang Bing Za Zhi. 2007 May;15(5):342-5. Zhonghua Gan Zang Bing Za Zhi. 2007. PMID: 17524265 Clinical Trial. Chinese.

9

[Week 24 suppression of HBV in entecavir-treated chronic hepatitis B patients in whom lamivudine treatment failed is associated with efficacy at week 48].

Ma H, Ren JB, Li HY, Wang Y, Wang RL, Liang L, Sun SJ, Jia JD. Ma H, et al. Among authors: jia jd. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007 Jun;21(2):102-4. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi. 2007. PMID: 17653304 Clinical Trial. Chinese.

10

[Factors associated with HBeAg seroconversion in chronic hepatitis B patients treated with interferon alfa-2a].

Li MH, Xie Y, Wu YZ, Xu DZ, Lu ZM, Hou JL, Jia JD, Wang YM, Zhang SL, Ren H, Chen XY. Li MH, et al. Among authors: jia jd. Zhonghua Gan Zang Bing Za Zhi. 2007 Jul;15(7):481-4. Zhonghua Gan Zang Bing Za Zhi. 2007. PMID: 17669233 Chinese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

521 results

Search Page

Filters